Eddie Hickman
Stock Analyst at Guggenheim
(4.42)
# 303
Out of 5,072 analysts
19
Total ratings
61.11%
Success rate
21.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PMN ProMIS Neurosciences | Maintains: Buy | $6 → $5 | $0.29 | +1,627.12% | 3 | Nov 18, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $84 → $87 | $80.50 | +8.07% | 9 | Nov 5, 2025 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $1.68 | - | 4 | Aug 29, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $8.60 | +155.81% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $14.75 | +116.95% | 1 | Mar 13, 2025 | |
| CYBN Cybin | Initiates: Buy | $35 | $6.03 | +480.43% | 1 | Mar 13, 2025 |
ProMIS Neurosciences
Nov 18, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $0.29
Upside: +1,627.12%
Tarsus Pharmaceuticals
Nov 5, 2025
Maintains: Buy
Price Target: $84 → $87
Current: $80.50
Upside: +8.07%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.68
Upside: -
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $8.60
Upside: +155.81%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $14.75
Upside: +116.95%
Cybin
Mar 13, 2025
Initiates: Buy
Price Target: $35
Current: $6.03
Upside: +480.43%